Emideltide (DSIP) Research: Sleep Evidence, Safety, and FDA Status

Emideltide is a nine-amino-acid peptide more commonly known as delta sleep-inducing peptide, or DSIP. It was isolated during sleep research in the 1970s and later studied in animals and small human experiments involving sleep, narcolepsy, and withdrawal symptoms.

The name suggests a clear sleep-inducing hormone with a defined mechanism. The evidence is more complicated. Older studies produced mixed findings, the molecular target remains uncertain, and FDA's 2026 review described the clinical evidence as insufficient. [1]

What Is Emideltide?

Emideltide is reported as the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. FDA's materials use “Emideltide” while recognizing DSIP as an alternate name. The agency evaluated Emideltide free base and Emideltide acetate as separate bulk drug substances. [1]

The peptide is short and susceptible to enzymatic breakdown. Research has detected fragments after exposure to peptidases in brain tissue, complicating attempts to identify which molecular species may be active. Its principal receptor, primary mechanism, and pharmacokinetic profile remain unresolved.

Research History

DSIP emerged from experiments that associated material collected during electrically induced sleep with increased delta-wave sleep in recipient animals. The sequence was isolated and synthesized, leading to a large but uneven literature across sleep physiology, stress, pain, endocrine signaling, and substance withdrawal.

Early enthusiasm was followed by inconsistent replication. Some studies reported changes in sleep architecture, while others found weak, variable, or no meaningful effects. The history is a useful example of why a biological name can become more certain than the underlying evidence.

Proposed Mechanisms

No single accepted mechanism explains the reported findings.

Central nervous system access

Animal research has examined whether DSIP crosses the blood-brain barrier. A dog study reported transport-related observations, but species differences and older analytical methods limit direct conclusions about human exposure. [4]

Neurotransmitter and stress systems

Preclinical studies have investigated relationships with GABAergic, glutamatergic, opioid, and stress-response systems. Results vary across species, route, timing, and analog. These findings support possible neuromodulatory activity but do not establish a clinically relevant target.

Metabolites and indirect effects

Because Emideltide is rapidly degraded, some reported activity could involve peptide fragments or indirect signaling. Without a defined receptor and validated pharmacokinetics, connecting an administered product to a specific effect remains difficult.

Human Sleep Studies

The human literature is old, small, and mixed.

A 1992 double-blind study enrolled 16 people with chronic insomnia. Investigators reported little therapeutic benefit overall: several objective and subjective measures did not differ meaningfully between Emideltide and placebo. [2]

Other small studies reported improvements compared with baseline or externally matched healthy controls, but FDA identified important limitations such as small samples, inadequate control groups, inconsistent baseline characteristics, different regimens, and uncertain clinical significance. [1]

The central question is not whether any sleep variable changed. It is whether a well-controlled study shows a reproducible, clinically meaningful benefit with acceptable risk. Current evidence does not answer that question.

Other Human Research

Emideltide has also been examined in limited studies involving narcolepsy and withdrawal symptoms.

An open clinical report evaluated DSIP during opioid detoxification. [3] Open-label studies without randomization, blinding, or an adequate comparison group cannot separate treatment effects from the natural course of withdrawal, supportive care, expectation, and concurrent interventions.

FDA concluded that the available studies for chronic insomnia were at best preliminary and that research involving narcolepsy and opioid withdrawal had major design limitations. The agency found no effectiveness data for the nominated subcutaneous route. [1]

Safety and Side Effects

The safety evidence depends strongly on route. FDA identified small human studies involving intravenous administration but no studies supporting the nominated subcutaneous route. [1]

In older intravenous studies, reports included transient headache, nausea, vertigo, and cases of progressive hypotension after a second injection in some participants with withdrawal symptoms. Interpretation is difficult because withdrawal itself can produce overlapping symptoms and the studies were not designed to establish adverse-event incidence.

Other safety gaps include:

No adequate long-term safety program
Limited pharmacokinetic information
Unknown immunogenicity
Potential aggregation or peptide-related impurities
Uncertain off-target activity
Limited information on repeated use

The word “natural” is sometimes applied to DSIP, but endogenous detection and exogenous administration are different questions. A manufactured peptide product can present risks related to exposure and quality that are not answered by the compound's proposed biological origin.

FDA and Compounding Status

Emideltide is not an FDA-approved drug. FDA evaluated the free-base and acetate forms for possible inclusion on the 503A Bulks List in connection with chronic insomnia, narcolepsy, and opioid withdrawal.

FDA concluded that the substances were not adequately characterized, effectiveness evidence was insufficient, safety information was incomplete, and approved therapies existed for the reviewed conditions. The agency proposed not adding either form to the list. [1]

PCAC is scheduled to discuss the proposal on July 24, 2026. The meeting will advise FDA; it will not approve Emideltide or immediately produce the agency's final determination. The FDA PCAC peptide review hub will be updated with the outcome.

Evidence Assessment

Evidence area	Current assessment
Peptide identity	Nine-amino-acid sequence described
Molecular target	Not established
Animal evidence	Broad but inconsistent
Human sleep evidence	Small, older, and mixed
Evidence for withdrawal or narcolepsy	Limited and methodologically weak
Long-term safety	Unknown
FDA approval	Not approved

Frequently Asked Questions

Is Emideltide the same as DSIP?

Yes. FDA's 2026 materials identify Emideltide as delta sleep-inducing peptide, commonly abbreviated DSIP.

Does DSIP induce deep sleep?

The name reflects the peptide's research history, not a settled clinical effect. Human studies have been small and inconsistent, and a controlled study in chronic insomnia reported little therapeutic benefit.

Is Emideltide FDA approved for insomnia?

No. It is not an FDA-approved insomnia drug. The July 2026 PCAC meeting concerns eligibility for the 503A compounding bulks list.

Are there human studies?

Yes, unlike several other peptides in the July meeting. However, the studies are generally old, small, use different designs and routes, and do not provide sufficient evidence of effectiveness or long-term safety.

Is DSIP a neuropeptide?

It is commonly discussed as a neuropeptide because of its origin in sleep research and proposed central effects. Its exact endogenous role, receptor, and mechanism remain uncertain. For wider context, see our neuropeptide overview.